Oseltamivir phosphate
Based on 46 publication(s) in Google Scholar
Oseltamivir phosphate (GS 4104) is a neuraminidase inhibitor recommended for the treatment and prophylaxis of influenza A and B.
For research use only. We do not sell to patients.
- Purity: 99.93%
- CAS No.: 204255-11-8
- Formula: C16H31N2O8P
- Molecular Weight:410.40
-
Storage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocol
- Purity & Documentation
- References
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
FDA-Approved Drug Library
HY-L022
-
Anti-Cancer Compound Library
HY-L025
-
Antiviral Compound Library
HY-L027
-
Drug Repurposing Compound Library
HY-L035
-
Anti-COVID-19 Compound Library
HY-L052
-
NMPA-Approved Drug Library
HY-L053
-
Orally Active Compound Library
HY-L061
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Drug-Induced Liver Injury (DILI) Compound Library
HY-L076
-
Rare Diseases Drug Library
HY-L102
-
Pediatric Drug Library
HY-L104
-
EMA-Approved Drug Library
HY-L116
-
FDA-Approved Anticancer Drug Library
HY-L122
-
Human Metabolite Library
HY-L123
-
Off-patent Drug Library
HY-L141
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
Publications Citing Use of MedChemExpress (MCE) Oseltamivir phosphate
More- Signal Transduct Target Ther. 2021 Apr 24;6(1):165. [Abstract]
- Nat Commun. 2026 Feb 19. [Abstract]
- NPJ Digit Med. 2025 Nov 21;8(1):712. [Abstract]
- Sci Transl Med. 2026 Feb 18;18(837):eadt3889. [Abstract]
- Acta Pharm Sin B. 2025 Aug;15(8):4156-4173. [Abstract]
- Phytomedicine. 2024 Jul:129:155534. [Abstract]
- Chemosphere. 2015 Jul:131:41-7. [Abstract]
- Arch Pharm Res. 2018 Jun;41(6):664-676. [Abstract]
- Biomed Pharmacother. 2018 Jan:97:385-394. [Abstract]
- Bioeng Transl Med. 2020 Dec 1;6(1):e10196. [Abstract]
- Cell Prolif. 2021 Jan;54(1):e12953. [Abstract]
- Virulence. 2024 Dec;15(1):2301242. [Abstract]
- J Ethnopharmacol. 2024 Jan 30;319(Pt 2):117290. [Abstract]
- Food Funct. 2016 Apr 20;7(4):2052-9. [Abstract]
- Commun Biol. 2026 Jan 26;9(1):324. [Abstract]
- Inflammation. 2024 Feb;47(1):30-44. [Abstract]
- Int J Mol Sci. 2025 Jun 3;26(11):5358. [Abstract]
- Int J Mol Sci. 2022 Apr 1;23(7):3940. [Abstract]
- Int J Mol Sci. 2019 Dec 12;20(24):6261. [Abstract]
- Pharmaceuticals (Basel). 2025 Aug 30;18(9):1306. [Abstract]
- J Med Virol. 2023 Jul;95(7):e28968. [Abstract]
- Int J Infect Dis. 2024 Jun 27:107134. [Abstract]
- Front Cell Dev Biol. 2021 Dec 17:9:802502. [Abstract]
- BMC Microbiol. 2025 May 15;25(1):292. [Abstract]
- Lab Invest. 2020 Dec;100(12):1602-1617. [Abstract]
- Virol Sin. 2026 Jan 29:S1995-820X(26)00011-8. [Abstract]
- Antiviral Res. 2025 May 3:106174. [Abstract]
- Virol Sin. 2024 Aug 19:S1995-820X(24)00134-2. [Abstract]
- Antiviral Res. 2020 Apr;176:104751. [Abstract]
- Antiviral Res. 2016 Mar:127:68-78. [Abstract]
- Sci Rep. 2021 Aug 11;11(1):16293. [Abstract]
- Virol J. 2025 Jun 4;22(1):181. [Abstract]
- ACS Infect Dis. 2025 Jun 13;11(6):1437-1447. [Abstract]
- Viruses. 2018 Jun 13;10(6). pii: E325. [Abstract]
- Animal Model Exp Med. 2025 Jan 26. [Abstract]
- Phytochemistry. 2023 Oct:214:113829. [Abstract]
- Chem Biodivers. 2024 Nov 24:e202402465. [Abstract]
- Virology. 2025 Oct:611:110642. [Abstract]
- Virology. 2024 Feb:590:109954. [Abstract]
- Virology. 2020 Jun;545:1-9. [Abstract]
- Biosci Biotechnol Biochem. 2020 Apr;84(4):774-779. [Abstract]
- bioRxiv. 2025 Jul 31.
- bioRxiv. 2024 Jul 7:2024.07.04.601620. [Abstract]
- bioRxiv. 2024 May 8:2024.05.06.592815. [Abstract]
- bioRxiv. 2023 Aug 12.
- Universidade de São Paulo. 2020 Sep.
Customer Validation & Images
-
Cell Imaging/Staining
-
WB
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
-
Histological Imaging/Staining
Biological Activity
Influenza A and B[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| MDCK | CC50 |
>100 μM
Compound: OSV-p
|
Cytotoxicity against dog MDCK cells assessed as reduction in cell viability measured after 40 hrs by Celltiter-Glo assay
Cytotoxicity against dog MDCK cells assessed as reduction in cell viability measured after 40 hrs by Celltiter-Glo assay
|
[PMID: 31425909] |
| MDCK | CC50 |
>100 μM
Compound: OSV-p
|
Cytotoxicity against dog MDCK cells assessed as cell viability measured after 45 hrs by Celltiter-Glo luminescence assay
Cytotoxicity against dog MDCK cells assessed as cell viability measured after 45 hrs by Celltiter-Glo luminescence assay
|
[PMID: 31635892] |
| MDCK | CC50 |
>100 μM
Compound: OSV-p
|
Cytotoxicity against MDCK cells assessed as reduction in cell viability by CellTiter-Glo assay
Cytotoxicity against MDCK cells assessed as reduction in cell viability by CellTiter-Glo assay
|
[PMID: 34795865] |
| MDCK | CC50 |
>100 μM
Compound: OSV-p
|
Cytotoxicity against dog MDCK cells assessed as reduction in cell viability incubated for 48 hrs by celltiter-glo assay
Cytotoxicity against dog MDCK cells assessed as reduction in cell viability incubated for 48 hrs by celltiter-glo assay
|
[PMID: 37354741] |
| MDCK | CC50 |
>163.26 μM
Compound: Oseltamivir phosphate
|
Cytotoxicity against MDCK cells assessed as reduction in cell viability after 24 hrs by MTT assay
Cytotoxicity against MDCK cells assessed as reduction in cell viability after 24 hrs by MTT assay
|
[PMID: 31559005] |
| MDCK | CC50 |
>200 μM
Compound: OSV-P
|
Cytotoxicity against MDCK cells after 40 hrs incubation by CellTiter-Glo assay
Cytotoxicity against MDCK cells after 40 hrs incubation by CellTiter-Glo assay
|
[PMID: 26866456] |
| MDCK | IC50 |
>500 μM
Compound: Oseltamivir, Tamiflu
|
Antiinfluenza activity against influenza B virus infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 36 hrs
Antiinfluenza activity against influenza B virus infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 36 hrs
|
[PMID: 22341943] |
| MDCK | IC50 |
1.1 μM
Compound: Oseltamivir, Tamiflu
|
Antiinfluenza activity against influenza A virus H3N2 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 36 hrs
Antiinfluenza activity against influenza A virus H3N2 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 36 hrs
|
[PMID: 22341943] |
| MDCK | IC50 |
15.5 μM
Compound: Oseltamivir, Tamiflu
|
Antiinfluenza activity against influenza A virus H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 36 hrs
Antiinfluenza activity against influenza A virus H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 36 hrs
|
[PMID: 22341943] |
| MDCK | IC50 |
45.6 μM
Compound: Osv-p, Tamiflu
|
Antiviral activity against Influenza A virus A/WSN/33 (H1N1) infected in MDCK cells assessed as inhibition of virus-induced cell death after 36 hrs by CellTiter-Glo luminescent cell viability assay
Antiviral activity against Influenza A virus A/WSN/33 (H1N1) infected in MDCK cells assessed as inhibition of virus-induced cell death after 36 hrs by CellTiter-Glo luminescent cell viability assay
|
[PMID: 24957203] |
| MDCK | IC50 |
45.6 μM
Compound: Osv-P; Tamiflu
|
Antiviral activity against Influenza A virus A/WSN/33(H1N1) infected in dog MDCK cells preincubated with virus for 15 mins followed by cells addition measured at 36 hrs post infection
Antiviral activity against Influenza A virus A/WSN/33(H1N1) infected in dog MDCK cells preincubated with virus for 15 mins followed by cells addition measured at 36 hrs post infection
|
[PMID: 26841168] |
Oseltamivir phosphate (OP) is a prodrug that is readily absorbed from the gastrointestinal tract after oral administration and is extensively converted predominantly by hepatic esterases to Oseltamivir carboxylate (OC)[1]. Oseltamivir phosphate is a widely used anti-influenza sialidase inhibitor. The metabolic activity of CMA07 and CMT-U27 cell lines is significantly decreased with 305 μM Oseltamivir phosphate treatment (p=0.005 and p<0.0001 respectively) using One Way ANOVA testes. In contrast, no statistically significant alterations are observed with 0.305 μM (p=0.9781), 3.05 μM (p=0.7436) and 30.5 μM (p=0.9623) of Oseltamivir phosphate treatments when compare with control cells. Finally, to assess the effect of Oseltamivir phosphate on CMA07 and CMT-U27 programmed cell death, and given that 305 μM Oseltamivir phosphate treatment impaired cell metabolic activity, a programmed cell death measurement is performed with the TUNEL assay. Twenty-four hour Oseltamivir phosphate treatment, specifically at 305 μM, significantly increases CMA07 (p=0.001) and CMT-U27 (p=0.0002) DNA fragmentation, suggesting promotion of programmed cell death, when compare with lower Oseltamivir concentrations, or with PBS[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 204255-11-8
-
Appearance Solid
-
Molecular Weight 410.40
-
Formula C16H31N2O8P
-
Color White to off-white
-
SMILES
O=C(OCC)C1=C[C@H]([C@@H]([C@H](C1)N)NC(C)=O)OC(CC)CC.OP(O)(O)=O
-
Synonyms
GS 4104 phosphate
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (46)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
An integrative drug repositioning framework discovered a potential therapeutic agent targeting COVID-19. [Abstract]2021 Apr 24;6(1):165. PMID: 33895786 -
Nat Commun
Baloxavir outperforms oseltamivir, favipiravir, and amantadine in treating lethal influenza A(H5N1) HA clade 2.3.4.4b infection in mice. [Abstract]2026 Feb 19. PMID: 41714318 -
NPJ Digit Med
Predictive modeling & mechanistic validation of synergistic pimodivir combinations for anti-influenza therapy via PB2cap affinity boost. [Abstract]2025 Nov 21;8(1):712. PMID: 41272280 -
Sci Transl Med
Baloxavir alleviates severe disease and viremia in ferrets infected with avian- or bovine-origin influenza A(H5N1) virus. [Abstract]2026 Feb 18;18(837):eadt3889. PMID: 41706870 -
Acta Pharm Sin B
A novel C-3-substituted oleanolic acid benzyl amide derivative exhibits therapeutic potential against influenza A by targeting PA-PB1 interactions and modulating host macrophage inflammation. [Abstract]2025 Aug;15(8):4156-4173. PMID: 40893672
Oseltamivir phosphate purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2025 Aug;15(8):4156-4173. [Abstract]
Six-week-old BALB/c mice were intranasally administered a 5-fold 50% lethal dose (LD50) of A/WSN/1933 and were treated with A5 or Oseltamivir phosphate (OSP)(i.p.; 6 d) or PBS 12 h later. Graphs of body weight curves and Kaplan—Meier survival curves of infected mice for 14 days were shown.
-
Phytomedicine
Insights into the mechanism of action of pterostilbene against influenza A virus-induced acute lung injury. [Abstract]2024 Jul:129:155534. PMID: 38583346 -
Chemosphere
Photocatalytic degradation of the antiviral drug Tamiflu by UV-A/TiO2: Kinetics and mechanisms. [Abstract]2015 Jul:131:41-7. PMID: 25765262 -
Arch Pharm Res
The inhibitory effect of sodium baicalin on oseltamivir-resistant influenza A virus via reduction of neuraminidase activity. [Abstract]2018 Jun;41(6):664-676. PMID: 29572682 -
Biomed Pharmacother
Oroxylin A suppresses influenza A virus replication correlating with neuraminidase inhibition and induction of IFNs. [Abstract]2018 Jan:97:385-394. PMID: 29091888 -
Bioeng Transl Med
IDentif.AI: Rapidly optimizing combination therapy design against severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Cov-2) with digital drug development. [Abstract]2020 Dec 1;6(1):e10196. PMID: 33532594 -
Cell Prolif
Direct inhibitory effect on viral entry of influenza A and SARS-CoV-2 viruses by azithromycin. [Abstract]2021 Jan;54(1):e12953. PMID: 33211371 -
Virulence
Immunosuppressants exert antiviral effects against influenza A(H1N1)pdm09 virus via inhibition on nucleic acid synthesis, mRNA splicing and protein stability. [Abstract]2024 Dec;15(1):2301242. PMID: 38170681 -
J Ethnopharmacol
Interpretation of the anti-influenza active ingredients and potential mechanisms of Ge Gen Decoction based on spectrum-effect relationships and network analysis. [Abstract]2024 Jan 30;319(Pt 2):117290. PMID: 37806538
Oseltamivir phosphate purchased from MedChemExpress. Usage Cited in: J Ethnopharmacol. 2024 Jan 30;319(Pt 2):117290. [Abstract]
Oseltamivir phosphate (OP) (21.2 mg/kg; p.o.; once daily for 7 d). Lung indexes on day 4 post-infection with H1N1 (0.8 LD50). Expression of H1N1-NP mRNA was measured using RT-PCR.
-
Food Funct
Neuraminidase inhibition of Dietary chlorogenic acids and derivatives - potential antivirals from dietary sources. [Abstract]2016 Apr 20;7(4):2052-9. PMID: 27010419 -
Commun Biol
Oseltamivir and baloxavir monotherapy and combination therapy efficacy against clade 2.3.4.4b A(H5N1) influenza virus infection in ferrets. [Abstract]2026 Jan 26;9(1):324. PMID: 41588212 -
Inflammation
Siglec-E Ligand Downregulation on Hippocampus Neurons Induced Inflammation in Sevoflurane-Associated Perioperative Neurocognitive Disorders in Aged Mice. [Abstract]2024 Feb;47(1):30-44. PMID: 37603227
Oseltamivir phosphate purchased from MedChemExpress. Usage Cited in: Inflammation. 2024 Feb;47(1):30-44. [Abstract]
Oseltamivir (OS) (30 or 100 μg/mL), a neuraminidase inhibitor, was used to block the increased neuraminidase effect induced by sevoflurane. 100 μg/mL Oseltamivir (OS) recovered the Siglec-E ligand level decrease in cultured primary hippocampal neurons.
-
Int J Mol Sci
Lycorine Inhibits Influenza Virus Replication by Affecting Nascent Nucleoporin Nup93 Synthesis. [Abstract]2025 Jun 3;26(11):5358. PMID: 40508167 -
Int J Mol Sci
Antiviral Effects of ABMA and DABMA against Influenza Virus In Vitro and In Vivo via Regulating the Endolysosomal Pathway and Autophagy. [Abstract]2022 Apr 1;23(7):3940. PMID: 35409297 -
Int J Mol Sci
Antiviral Activity of Benzoic Acid Derivative NC-5 Against Influenza A Virus and Its Neuraminidase Inhibition. [Abstract]2019 Dec 12;20(24):6261. PMID: 31842256
Oseltamivir phosphate purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2019 Dec 12;20(24):6261. [Abstract]
The ICR mice were infected with influenza A virus (8 × LD50) and received Oseltamivir phosphate (OS) (100 mg/kg; twice daily for 5 days).
-
Pharmaceuticals (Basel)
Herbacetin Alleviates Influenza Virus-Induced Lung Injury and Fibrosis by Targeting the Neuraminidase Protein. [Abstract]2025 Aug 30;18(9):1306. PMID: 41011177
Oseltamivir phosphate purchased from MedChemExpress. Usage Cited in: Pharmaceuticals (Basel). 2025 Aug 30;18(9):1306. [Abstract]
Oseltamivir (OSE) (15 mg/kg/day; i.p.) did not cause significant weight loss or mortality after viral infection in the mice. Lung index data showed that Oseltamivir (OSE) treatment significantly reduced lung inflammation.
Oseltamivir phosphate purchased from MedChemExpress. Usage Cited in: Pharmaceuticals (Basel). 2025 Aug 30;18(9):1306. [Abstract]
Oseltamivir (OSE) (15 mg/kg/day; i.p.) treatment markedly reduced collagen deposition. Statistical data on inflammatory infiltration, pulmonary edema, and fibrotic area were provided. These results indicated that Oseltamivir (OSE) reduced lung injury and PF induced by IAV in vivo.
Oseltamivir phosphate purchased from MedChemExpress. Usage Cited in: Pharmaceuticals (Basel). 2025 Aug 30;18(9):1306. [Abstract]
Results from immunohistochemical analysis for TGF-β1, collagen I, and Fn in the lung tissues from each group of mice were provided, accompanied by relevant statistical data. The Oseltamivir (OSE) (15 mg/kg/day; i.p.) group demonstrated reductions in these proteins within lung tissue.
-
J Med Virol
Discovery of ligustrazine and chalcone derivatives as novel viral nucleoprotein nuclear export inhibitors against influenza viruses. [Abstract]2023 Jul;95(7):e28968. PMID: 37489704 -
Int J Infect Dis
Antiviral susceptibility of SARS-CoV-2 and influenza viruses from 3 co-infected pediatric patients. [Abstract]2024 Jun 27:107134. PMID: 38944411 -
Front Cell Dev Biol
Neuraminidase1 Inhibitor Protects Against Doxorubicin-Induced Cardiotoxicity via Suppressing Drp1-Dependent Mitophagy. [Abstract]2021 Dec 17:9:802502. PMID: 34977042 -
BMC Microbiol
2025 May 15;25(1):292. PMID: 40375181 -
Lab Invest
Hepatitis B virus core protein promotes the expression of neuraminidase 1 to facilitate hepatocarcinogenesis. [Abstract]2020 Dec;100(12):1602-1617. PMID: 32686743
Oseltamivir phosphate purchased from MedChemExpress. Usage Cited in: Lab Invest. 2020 Dec;100(12):1602-1617. [Abstract]
After the HBc-positive cells are treated with OP (Oseltamivir phosphate), the phosphorylation of ERK and P65 significantly declined, the expression of IkBα increased, and the expression of nuclear P65 decreased.
-
Virol Sin
2026 Jan 29:S1995-820X(26)00011-8. PMID: 41619854
Oseltamivir phosphate purchased from MedChemExpress. Usage Cited in: Virol Sin. 2026 Jan 29:S1995-820X(26)00011-8. [Abstract]
MDCK-PB2 cells were infected with H5N1/ΔPB2(300)-rGFP and then maintained in medium containing Oseltamivir (0.01–100 μM; 48 h; 37℃). The fluorescence microscopy images of the infected cells were recorded.
Oseltamivir phosphate purchased from MedChemExpress. Usage Cited in: Virol Sin. 2026 Jan 29:S1995-820X(26)00011-8. [Abstract]
Detection of NP expression in H1N1/ΔPB2(300)-rGFP infected and Oseltamivir (0.01–100 μM; 48 h; 37°C) treated MDCKPB2 cells.
-
Antiviral Res
Influenza A(H1N1)pdm09 virus resistance to baloxavir, oseltamivir and sialic acid mimetics in single and dual therapies: Insights from human airway epithelia and murine models. [Abstract]2025 May 3:106174. PMID: 40324597 -
Virol Sin
Antiviral activity of vitamin D derivatives against severe fever with thrombocytopenia syndrome virus in vitro and in vivo. [Abstract]2024 Aug 19:S1995-820X(24)00134-2. PMID: 39168248 -
Antiviral Res
Prophylaxis of ferrets with nitazoxanide and oseltamivir combinations is more effective at reducing the impact of influenza a virus infection compared to oseltamivir monotherapy. [Abstract]2020 Apr;176:104751. PMID: 32088248 -
Antiviral Res
Antiviral activity of SA-2 against influenza A virus in vitro/vivo and its inhibition of RNA polymerase. [Abstract]2016 Mar:127:68-78. PMID: 26802558 -
Sci Rep
Substitution of I222L-E119V in neuraminidase from highly pathogenic avian influenza H7N9 virus exhibited synergistic resistance effect to oseltamivir in mice. [Abstract]2021 Aug 11;11(1):16293. PMID: 34381119 -
Virol J
Bisbenzylisoquinoline alkaloids inhibit influenza virus replication by disrupting endosomal acidification. [Abstract]2025 Jun 4;22(1):181. PMID: 40468427 -
ACS Infect Dis
Development of a Universal Type A Influenza Viral RdRp-Induced Reporter System with Potential for Antiviral Drug Screening. [Abstract]2025 Jun 13;11(6):1437-1447. PMID: 40421776 -
Viruses
A Simple and Robust Approach for Evaluation of Antivirals Using a Recombinant Influenza Virus Expressing Gaussia Luciferase. [Abstract]2018 Jun 13;10(6). pii: E325. PMID: 29899269 -
Animal Model Exp Med
2025 Jan 26. PMID: 39865580 -
Phytochemistry
Pogocablenes A-O, fifteen undescribed sesquiterpenoids with structural diversity from Pogostemon cablin. [Abstract]2023 Oct:214:113829. PMID: 37597718 -
Chem Biodivers
Highly Conjugated Ergosterols With Anti-Influenza Virus Activity From the Marine-Derived Fungus Eutypella Sp. F0219. [Abstract]2024 Nov 24:e202402465. PMID: 39581859 -
Virology
The combinatorial activities of oseltamivir and molnupiravir against influenza virus infections in vitro and in vivo. [Abstract]2025 Oct:611:110642. PMID: 40730007 -
Virology
Recombinant A(H6N1)-H274Y avian influenza virus with dual drug resistance does not require permissive mutations to retain the replicative fitness in vitro and in ovo. [Abstract]2024 Feb:590:109954. PMID: 38086284 -
Virology
Effectiveness of favipiravir (T-705) against wild-type and oseltamivir-resistant influenza B virus in mice. [Abstract]2020 Jun;545:1-9. PMID: 32174453 -
Biosci Biotechnol Biochem
Orientin suppresses oxidized low-density lipoproteins induced inflammation and oxidative stress of macrophages in atherosclerosis. [Abstract]2020 Apr;84(4):774-779. PMID: 31829093 -
-
bioRxiv
Rebalancing Viral and Immune Damage versus Tissue Repair Prevents Death from Lethal Influenza Infection. [Abstract]2024 Jul 7:2024.07.04.601620. PMID: 39372755 -
bioRxiv
Oseltamivir (Tamiflu), a Commonly Prescribed Antiviral Drug, Mitigates Hearing Loss in Mice. [Abstract]2024 May 8:2024.05.06.592815. PMID: 38765999 -
-
Solvent & Solubility
H2O : 100 mg/mL (243.66 mM; Need ultrasonic)
DMSO : 100 mg/mL (243.66 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.09 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.09 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
Protocol
CMA07 and CMT-U27 cells are cultured in 24-well plates in triplicate for each condition: 0.305 μM, 3.05 μM, 30.5 μM and 305 μM Oseltamivir phosphate and PBS is used as control. Cells are counted every day for 7 days in a Neubauer’s chamber in a 1:2 dilution of cells in 0.4% trypan blue and cell count is done using the volume conversion factor for 1 mm3, which is 1×104. This assay is repeated 3 times and growth curves are traced[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Mice[2]
Female NIH(S)II-nu/nu nude mice, aged 4-6 weeks, are orthotopically inoculated with 1×106 viable CMT-U27 canine breast cancer cells in the mammary fat pad using a 25 gauge needle. A total of 8 mice are inoculated. When nodules reached a volume of approximately 500 mm3, mice (n=8) are randomized and divided into control group (n=4) and treatment group (n=4).The animals receive intraperitoneally (IP) dailly either 100 μL of PBS (control group) or 100mg/Kg of Oseltamivir phosphate, diluted in PBS (treatment group) until time of death. Tumor size is measured using calipers, and tumor volume (mm3) is estimated by width×length×height.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (281 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Handling Instructions (2659 KB)
References
[1]. Huang H, et al. Transplacental transfer of Oseltamivir phosphate and its metabolite Oseltamivir carboxylate using the ex vivo human placenta perfusion model in Chinese Hans population. J Matern Fetal Neonatal Med. 2016 Aug 8:1-5. [Content Brief]
[2]. de Oliveira JT, et al. Anti-influenza neuraminidase inhibitor Oseltamivir phosphate induces canine mammary cancer cell aggressiveness. PLoS One. 2015 Apr 7;10(4):e0121590. [Content Brief]
[3]. Li P, et al. A Simple and Robust Approach for Evaluation of Antivirals Using a Recombinant Influenza Virus Expressing Gaussia Luciferase. Viruses. 2018 Jun 13;10(6). pii: E325. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 2.4366 mL | 12.1832 mL | 24.3665 mL | 60.9162 mL |
| 5 mM | 0.4873 mL | 2.4366 mL | 4.8733 mL | 12.1832 mL | |
| 10 mM | 0.2437 mL | 1.2183 mL | 2.4366 mL | 6.0916 mL | |
| 15 mM | 0.1624 mL | 0.8122 mL | 1.6244 mL | 4.0611 mL | |
| 20 mM | 0.1218 mL | 0.6092 mL | 1.2183 mL | 3.0458 mL | |
| 25 mM | 0.0975 mL | 0.4873 mL | 0.9747 mL | 2.4366 mL | |
| 30 mM | 0.0812 mL | 0.4061 mL | 0.8122 mL | 2.0305 mL | |
| 40 mM | 0.0609 mL | 0.3046 mL | 0.6092 mL | 1.5229 mL | |
| 50 mM | 0.0487 mL | 0.2437 mL | 0.4873 mL | 1.2183 mL | |
| 60 mM | 0.0406 mL | 0.2031 mL | 0.4061 mL | 1.0153 mL | |
| 80 mM | 0.0305 mL | 0.1523 mL | 0.3046 mL | 0.7615 mL | |
| 100 mM | 0.0244 mL | 0.1218 mL | 0.2437 mL | 0.6092 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Powered by Bioz